Document Detail

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus.
MedLine Citation:
PMID:  21444868     Owner:  NLM     Status:  Publisher    
PURPOSE Pneumonitis has occurred in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). In a phase III study of patients with previously untreated, poor-prognosis, advanced renal cell carcinoma (ARCC), the mTOR inhibitor temsirolimus improved survival compared with interferon. We performed a retrospective, independent, blinded radiographic review of chest computed tomography (CT) images of patients in this study to characterize temsirolimus-related pneumonitis. PATIENTS AND METHODS Patients were treated with intravenous temsirolimus 25 mg once weekly or subcutaneous interferon alfa 3 million units, with an increase to 18 million units, thrice weekly. Drug-related pneumonitis was identified based on sequential chest CT images, required every 8 weeks, showing changes consistent with pneumonitis and not pneumonia (infection) or disease progression as correlated with clinical data. Cumulative probability of drug-related pneumonitis was estimated using the Kaplan-Meier method. Results Eight (6%) of 138 and 52 (29%) of 178 evaluable patients on interferon and temsirolimus treatment, respectively, developed radiographically identified drug-related pneumonitis. Time to onset of pneumonitis was significantly shorter on the temsirolimus arm than on the interferon arm (log-rank P < .001). Estimated cumulative probability of pneumonitis at 8 and 16 weeks from first dose was 21% and 31%, respectively, on the temsirolimus arm and 6% and 8%, respectively, on the interferon arm. Respiratory symptoms were observed around time of onset of radiographically diagnosed temsirolimus-related pneumonitis in 16 (31%) of 52 patients. CONCLUSION Patients with ARCC receiving temsirolimus should be monitored closely for development of pneumonitis, and their management should be altered if clinical symptoms appear.
Jose Pablo Maroto; Gary Hudes; Janice P Dutcher; Theodore F Logan; Charles S White; Mizue Krygowski; Maria Cincotta; Mark Shapiro; Ignacio Duran; Anna Berkenblit
Related Documents :
19543748 - Genetic diversity of dientamoeba fragilis isolates of irritable bowel syndrome patients...
9200078 - Do children with repaired low anorectal malformations have normal bowel function?
14727498 - Transcutaneous electrical acustimulation can reduce visceral perception in patients wit...
15677908 - Small intestine contrast ultrasonography: an alternative to radiology in the assessment...
17524198 - Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active a...
21975338 - Change of telomerase activity in peripheral whole blood of head and neck squamous cell ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-28
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  -     ISSN:  1527-7755     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Sant Pau Hospital, Barcelona; Centro Integral Oncologico "Clara Campal," Madrid, Spain; Fox Chase Cancer Center, Philadelphia, PA; New York Medical College, Bronx, NY; Indiana University Simon Cancer Center, Indianapolis, IN; University of Maryland Medical Center, Baltimore, MD; and Pfizer, Cambridge, MA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without...
Next Document:  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospe...